Eye gaze and brain computer interface

Summary

This study aims to improve brain-computer interfaces (BCIs) for children with severe disabilities, such as quadriplegic cerebral palsy (qCP). Currently, BCIs assist individuals in controlling things with their minds, but they are not as effective for children with disabilities who may have difficulty focusing their eyes. The study hypothesizes that by only using brain signals when the children are looking straight ahead, the BCIs may work better. To test this idea, we will involve ten children diagnosed with cerebral palsy and ten children with typical development aged 4 to 16. During the study, they will play a fun game while we measure their brain waves, eye movements, and record a video. We will compare the effectiveness of the BCI when focusing only on moments when the children are looking straight ahead versus not doing so. If our hypothesis proves correct, this improvement could significantly benefit these children, enabling them to perform more tasks independently.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 4 to 16

Accepts healthy participants: Yes

Inclusion criteria:

1. Age 4-16 years.
2. Severe motor disability (GMFCS 5, MACS5)
3. Controls with no neurodevelopmental conditions or medications.
4. Written consent/assent.

Exclusion criteria:

1. Severe or unstable epilepsy
2. Behavioral or mental health disorder preventing training or compliance.
3. Children with severe visual impairment will be excluded because the application requires visual interaction with the screen.

Participate

Fill out the following form if you want to participate in this research

Method of contact

Collection of personal information
Your personal information is collected under the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If you have any questions about the collection or use of this information, please visit our Access to Information page.

Additional information

Contact information

Please reach out by email

Principal investigator:

C. Adam Kirton

Clinical trial:

No

REB-ID:

REB24-0564